Table1.

Demographic, Neurocognitive, and Clinical Information

	HC (N = 24)	FESZ (N = 18)	Statistic
			t or χ2	df	P
Female sex, N (%)	11 (45.8)	5 (27.8)	1.42	1	.23
Age at baseline	20.0 (3.85)	21.7 (4.55)	3.85	40	.18
Age at follow-up	21.0 (3.87)	22.8 (4.54)	3.87	40	.17
Inter-EEG interval (mo)	12.7 (4.03)	11.7 (3.33)	4.03	40	.38
Handednessa	0.7 (2.46)	1.9 (3.25)	2.46	40	.17
Education years	13.4 (2.67)	14.1 (2.69)	2.67	40	.45
Parental SESb	1.7 (0.91)	2.2 (1.17)	0.91	40	.12
Current IQc	117.9 (23.66)	105.5 (14.54)	23.66	39	.06
Premorbid IQd	118.4 (15.58)	111.2 (16.41)	15.58	40	.15
GAF
Baseline	84.1 (6.94)	49.4 (13.40)	10.91	40	<.001*
Follow-up	82.5 (9.51)	62.1 (15.52)	5.19	39	<.001*
BPRS Total Score
Baseline		44.0 (13.7)
Follow-up		35.8 (10.6)
BPRS Positive Symptom Score
Baseline		9.2 (3.9)
Follow-up		7.0 (2.5)
BPRS Negative Symptom Score
Baseline		11.8 (5.2)
Follow-up		9.4 (2.6)
Spatial Span subtest of the Wechsler Memory scale
Baseline	20.3 (3.6)	16.9 (2.9)	3.2	39	.003**
Follow-up	19.8 (3.1)	16.4 (3.7)	3.2	39	.003**
Medication (CPZ equivalents)
Baseline		267.9 (206.8)
Follow-up		300.0 (300.4)

Note: Values are means (SDs) unless otherwise indicated. SES, socioeconomic status; CPZ, chlorpromazine.

^aBased on the Annett Handedness Scale total score.

^bBased on the Hollingshead method. Higher scores indicate lower socioeconomic status.

^cEstimated from Vocab and Block Design T-scores of Wechsler Abbreviated Scale of Intelligence.

^dEstimated from Reading scale of Wide Range Achievement Test.

*Patients with first-episode schizophrenia showed significantly lower Global Assessment of Functioning scale scores compared with healthy comparison subjects both at baseline and follow-up.

**Patients with first-episode schizophrenia showed significantly lower Spatial Span scores compared with healthy comparison subjects both at baseline and follow-up.